Boston Scientific predicts even better second half
This article was originally published in Clinica
Boston Scientific expects an acceleration in sales and earnings in the second half of the year, once its NIR stent becomes available in the US and the acquisition of Schneider is completed. The company has already had sales growth of 7% and 8% in the quarter and first half - to $506 million and $976 million.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.